Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antitumor, monoclonal antibodies | 5762 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Datopotamab deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 4, 2025 | EMA | Daiichi Sankyo Europe GmbH | |
| Jan. 1, 2025 | FDA | Daiichi Sankyo (AstraZeneca) | |
| Dec. 12, 2024 | PMDA | Daiichi Sankyo Company, Limited |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Disease progression | 305.36 | 74.79 | 80 | 338 | 156535 | 90471494 |
| Stomatitis | 157.28 | 74.79 | 55 | 363 | 274643 | 90353386 |
| No adverse event | 85.53 | 74.79 | 25 | 393 | 67957 | 90560072 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Disease progression | 234.36 | 79.09 | 64 | 245 | 243970 | 110345020 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FX35 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates |
| MeSH PA | D000074322 | Antineoplastic Agents, Immunological |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D018796 | Immunoconjugates |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Metastatic hormone receptor-positive cancer; HER2-negative breast cancer | indication | 417181009 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tumor-associated calcium signal transducer 2 | Tumour-associated antigen | BINDING AGENT | EC50 | 9.13 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 2238831-60-0 | SECONDARY_CAS_RN |
| CHEMBL4297939 | ChEMBL_ID |
| C000731951 | MESH_SUPPLEMENTAL_RECORD_UI |
| 13304 | IUPHAR_LIGAND_ID |
| DB16410 | DRUGBANK_ID |
| 4043693 | VANDF |
| C5432272 | UMLSCUI |
| CHEBI:757370 | CHEBI |
| 11218 | INN_ID |
| D12359 | KEGG_DRUG |
| 392118 | MMSL |
| 43685 | MMSL |
| d10252 | MMSL |
| 019980 | NDDF |
| GD2OWY1DTK | UNII |
| 2703033 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| DATROWAY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65597-801 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | BLA | 32 sections |